ArticleBlood advances2021

Renal response in real-world carfilzomib- vs bortezomib-treated patients with relapsed or refractory multiple myeloma.

Shaji Kumar et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.